Company profile: Cagent Vascular
1.1 - Company Overview
Company description
- Provider of serration technology for treating cardiovascular disease, offering the Serranator PTA Serration Balloon Catheter, an angioplasty device with serrated metal strips on a semi-compliant balloon that creates multiple longitudinal micro-serrations to aid arterial expansion.
Products and services
- Cardiovascular Serration Technology Platform: Platform-level serration technology engineered to improve cardiovascular disease treatment by enabling interrupted micro-serrations and arterial expansion
- Serranator PTA Serration Balloon Catheter: Catheter-based angioplasty device with serrated metal strips embedded on a semi-compliant balloon creating multiple longitudinal interrupted micro-serrations aiding arterial expansion
- Micro-Serration Arterial Expansion Method: Device-integrated technique forming multiple longitudinal lines of interrupted micro-serrations via serrated metal strips embedded on a semi-compliant balloon to assist arterial expansion
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cagent Vascular
LeMaitre
HQ: United States
Website
- Description: Provider of medical devices and implants for the treatment of peripheral vascular diseases, including RestoreFlow, a tissue processing division supplying human tissue allografts for peripheral vascular and cardiac disease, and the LeMaitre Valvulotome, a device that cuts valves in peripheral veins without direct vision for lower extremity arterial disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LeMaitre company profile →
RR Mechatronics
HQ: The Netherlands
Website
- Description: Provider of analytics laboratory instruments for the medical diagnosis industry.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RR Mechatronics company profile →
Atacor
HQ: United States
Website
- Description: Provider of extravascular cardiac lead systems enabling defibrillation, bradycardia pacing, and anti-tachycardia pacing without contacting the heart or vascular system, including the AtaCor EV-ICD Lead System and the EV Temporary Pacing Lead System that provides pacing support via a parasternal approach.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atacor company profile →
Exithera Pharmaceuticals
HQ: United States
Website
- Description: Provider of antithrombotic and stroke prevention drug development, offering novel, potent, selective small-molecule Factor XIa inhibitors, including frunexian to prevent thrombosis without increased bleeding risk, and EP-7041 evaluated in a Phase 2 trial to prevent thrombosis in COVID-19 ICU patients and investigated to inhibit ECMO-related thrombosis while minimizing bleeding risk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exithera Pharmaceuticals company profile →
Recovery Force
HQ: United States
Website
- Description: Provider of MORPH, an on-body pre recovery and performance enhancement system, developed and manufactured by Recovery Force.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Recovery Force company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cagent Vascular
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cagent Vascular
2.2 - Growth funds investing in similar companies to Cagent Vascular
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cagent Vascular
4.2 - Public trading comparable groups for Cagent Vascular
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →